Italy: Clinical Trials Regulation v. GDPR: How Data Protection Affects Research Under Italian Data Protection Rules

Last Updated: 9 November 2018
Article by Giangiacomo Olivi

The way clinical trials have been conducted in the European Union is actually undergoing two major challenges: the coming into effect of Regulation (EU) no. 536/2014 (so-called Clinical Trial Regulation) and the application of the General Data Protection Regulation or GDPR.

On the one hand, the Clinical Trial Regulation will create a consistent framework of rules applicable to clinical trials at the European level, which will then require implementation from all member states. On the other, GDPR is the much talked about piece of legislation concerning the protection and free movement of personal data in the EU, whose specific impact on clinical trials is yet to be seen.

The crossroad between GDPR and the Clinical Trial Regulation is an important one. This because the wide use of internet, electronic records and new technologies enabling the collection of massive amounts of data is becoming increasingly important in clinical, pharmaceutical and biomedical research. In fact, this is posing new challenges to data security as well as to the protection of privacy of individuals.

New GDPR rules apply to nearly every sector and industry, as they have strengthened data subjects' rights and controller / processor obligations in the processing, sharing and transfer of personal data. However, such new rules do not necessarily fit with other sector specific legislation where the collection and use of large quantities of data is vital and sometimes imperative to achieve some goals, such as developing a new drug, medicine or service.

To this extent, GDPR raises some important questions for clinical trials, a fundamental aspect of which is the collection and analysis of the so-called special categories of personal data (e.g., health related data, genetic data, biometric data, etc.). The GDPR strongly protects these special categories of data, as they are also at the very centre of each clinical trial performed for scientific, statistical or research purposes.

For instance, for the processing of genetic or health related data, new privacy rules imposes that those entities processing such data must collect consent according to clarity, intelligibility, transparency and substantial burden of proof requirements. Furthermore, every collection and use of personal data or special categories of data shall comply with data minimization and privacy by design and by default principles, as well as adequate security standards. In addition, the vast use of special categories of personal data may impose on controllers the obligations to perform a so-called Data Protection Impact Assessment (DPIA) pursuant to art. 35 GDPR. In fact, the duty to comply with these obligations shall be specifically included in detailed agreements regulating the relationship and goals between the owner of the data (controller) and its operational arm (processor).

Despite the above, many of the responsibilities and obligations defined by GDPR are not new to companies operating in the clinical research sector, thus including that of informed consent. In fact, clinical research operators have long been subject to very stringent rules in various jurisdictions around the world concerning data security and the use of health related information for different purposes – think of, among others, the US HIPAA, Regulation (EU) no. 726/2004 and the European Pharmacovigilance Package of 2010-12.

So what is the big deal between GDPR and the Clinical Trial Regulation?

The issue is the possibility to collect and use personal data and special categories of personal data for clinical and research purposes under a particular regime of exception from general data protection rules, on the basis of which research becomes a legal basis for the processing.

As of today, there are some openings in the GDPR pointing in that direction (e.g., Recital 47, 50 and 157 or Art. 6(1)(f), 5(1)(e) and 89), although their interaction with the new provisions of the Clinical Trial Regulation are yet to be assessed. What is clear, though, is that the GDPR adopts a broad definition of research that encompasses all the activities of both public and private entities and finds its common denominator in big data analytics technologies and legitimate interest of clinical research providers, acting as controller.

In the eyes of the GDPR, determining the existence of a solid legitimate interest requires a "careful prior assessment" at the time and in the context of the collection of personal data. However, on the other hand, the use and secondary processing of vast amount of data for clinical and biomedical research purposes is already there and cannot be stopped.

According to the European Medicine Agency (EMA), the use of big data in medicines development and regulatory science will boom in the coming years. To this extent, the Clinical Trial Regulation will bring significant innovation in relation to the procedures to gather and make available the data necessary to conduct a clinical trial and obtain all the required authorization to initiate it.

In effect, the Clinical Trial Regulation also addresses the "over bureaucratization" of authorization procedures at the European level with the aim to speed up trial tests by introducing a common and harmonized procedure applicable in all member states. In this view, the Clinical Trial Regulation will also set the basis for the construction of a freely accessible EU clinical trial portal and database containing information on all ongoing clinical trials in the EU.

In theory, such database should not contain personal data or special categories of personal data referring to individuals undertaking clinical and biomedical trials. However, any other information concerning trials will be publicly available and freely accessible by interested healthcare and clinical research providers. This will indeed create new economic opportunities in the life sciences sector, although it may also affect data protection and privacy.

In fact, the Clinical Trial Regulation states that information contained in the clinical trial database should be public, unless specific reasons require that a piece of information should not be published, in order to protect the right of the individual to private life and the right to the protection of personal data as per the EU Charter of Fundamental Rights – whose core principles have been included in all European data protection laws and regulations.

The GDPR is very clear about the protection of special categories of personal data, and it provides for member states to set out rules that are more stringent in order to do it properly and in coordination with other more sector-specific rules (i.e., art. 9(4) GDPR). For instance, the recently reformed Italian Data Protection Code (DPC), as amended by Legislative Decree no. 101/2018, provided that the Italian Data Protection Authority (the Garante) shall issue biannual guidance / specific authorization on the processing of certain categories of personal data, thus including health-related, genetic and biometric data. This guidance is still a work in progress, as the Garante did not release any official statement on the timing for its future publication and implementation.

In addition to this, we note that the DPC also goes in a slightly different direction than the GDPR when it comes to processing activities for research purposes, thus including clinical trials. In fact, the issue of secondary processing is subject to a provision of the DPC stating that the Garante shall authorize each re-use of personal data for medical and scientific research purposes prior to the start of such processing (i.e., art. 110-bis of the DPC).

Indeed, it is unclear what will be the interplay between this provision and the future guidance of the Garante on the processing of special categories of personal data, nor it is foreseeable how these rules will affect the implementation of the Clinical Trials Regulation in Italy. In fact, we expect more indications and guidelines on this topic to be issued and published in the coming months, hopefully alongside a coordinated effort of regulators active in different areas such as data protection, life sciences and healthcare services.

Do you have more questions or you want to share your thoughts on this article? Contact our Dentons Italy TMT Team.

This article was co-authored by Francesco Armaroli and Fabiola Moretta

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions